ADCC, CDC and ADCP Assay Services for Brain Tumors

ADCC, CDC, and ADCP assay services for brain tumors

Antibodies consist of an antigen-binding site (Fab) and a crystallizable site (Fc). The structure of an antibody determines its mechanism of action, and the Fc segment then determines the effector function of the antibody, including antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cell-mediated phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC). ADCC, CDC, and ADCP are now important mechanisms by which many antibody drugs exert tumor killing, and brain tumor studies are also applied.

Our ADCC, CDC, and ADCP assay services for brain tumors

The detection of ADCC, CDC, and ADCP activity of antibodies and the further analysis of the strength of ADCC, CDC, and ADCP activity of antibodies have become critical steps in the development and quality control of antibody drugs. Alfa Cytology offers an in vitro antibody functional activity assay service for ADCC, CDC, and ADCP in brain tumor research to detect and evaluate the efficacy of antibodies or target cells.

ADCC assays

Target cells	Effector cells	Features	Applications
Cancer cell lines	Primary PBMC/NK cells	Close to in vivo immune microenvironment.	Late functional confirmation of antibody screening.
Engineered cell lines overexpressing targets	Primary PBMC/NK cells	Close to the true killing effect of human immune cells, the use of overexpressed cell lines for target cells will increase the success rate of the experiment.	Early screening or late functional confirmation of antibodies.
Cancer cell lines/engineered cell lines overexpressing targets	ADCC reporter cell lines	Low cost, high reproducibility, and high success rate.	Antibody early screening, CMC stage quality release.

CDC assays

Fluorescent dye labeling
Taipan blue labeling
LDH assay
calcein-AM labeling
Alamar blue labeling
CCK-8
51Cr release assay

ADCP assays

Target cells	Effector cells	Features	Applications
Cancer cell lines	M1/M2 type macrophages	The model is closer to the in vivo immune microenvironment.	Late functional confirmation of antibody screening.
Engineered cell line overexpressing target	M1/M2 type macrophages	This model is close to the real phagocytosis effect of human-derived macrophages and has a higher success rate.	Early screening or late functional confirmation of antibodies.
Target overexpression-engineered cell lines	ADCP reporter cell line	This model has low cost, high reproducibility, and a high success rate.	Antibody early screening, CMC stage quality release.

Our advantages

Rich experimental experience in projects.
Full QC protocols for macrophages during differentiation and maturation.
The use of complement molecules as CDC effector molecules provides more consistent results.
Primary effector cells are subjected to functional ADCC screening to improve the one-time success rate of the assay.
We have methodologically validated ADCC and ADCP reporter gene cell line assays.

Alfa Cytology will consider every potential experimental risk during the evaluation of your project, and use our extensive project experience to tailor experimental protocols to protect your project. Please contact our staff to submit your project requirements.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.